Evidence map›Paper›PMID 40260280›Full record

ArticleFrontiers in endocrinology2025

Advancing patient evidence in XLH (APEX): rationale and design of a real-world XLH global data unification program.

Maria Luisa Brandi, Thomas O Carpenter, Seiji Fukumoto, Dieter Haffner, Erik A Imel, Masanori Kanematsu, Keith P McCullough, Keiichi Ozono

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. FGF23　- A hormone produced by bone and has many faces.Reviews in endocrine & metabolic disorders · 2026
    Review
  2. Real-world impact of treatment on growth in children with X-linked hypophosphatemia.The Journal of clinical endocrinology and metabolism · 2026
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria Luisa BrandiFondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO), Florence, Italy.
Thomas O CarpenterDepartment of Pediatrics, Section of Endocrinology, Yale School of Medicine, New Haven, CT, United States.
Seiji FukumotoTamaki - Aozora Hospital, Tokushima, Japan.
Dieter HaffnerDepartment for Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School, Hannover, Germany.
Erik A ImelDepartments of Medicine and Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States.
Masanori KanematsuKyowa Kirin Corporation, Tokyo, Japan.
Keith P McCulloughArbor Research Collaborative for Health, Ann Arbor, MI, United States.
Keiichi OzonoISEIKAI International General Hospital, Osaka, Japan.

Funding

Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI GERALD I SHULMAN · 1993 to 2026
$44.0M
NIDDK NIH HHS P30 DK045735
6 · The paper itself

Abstract

X-linked hypophosphatemia (XLH) is a rare, genetic, progressive, lifelong disorder caused by pathogenic variants in the

Indexed as

Antibodies, Monoclonal, HumanizedFamilial Hypophosphatemic RicketsChildFibroblast Growth Factor-23HumansMaleMulticenter Studies as TopicObservational Studies as TopicRegistriesAntibodies, Monoclonal, HumanizedburosumabFGF23 protein, humanFibroblast Growth Factor-23Advancing Patient Evidence in XLH (APEX)fibroblast growth factor 23 (FGF23)musculoskeletalodontomalaciaosteomalaciaphosphate-regulating endopeptidase homologX-linked (PHEX) genericketsX-linked hypophosphatemia (XLH)

Identifiers

PMID40260280
PMCPMC12009718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.